



# ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: [www.americasblood.org](http://www.americasblood.org)

2024 #4

January 26, 2024

## INSIDE:

NHSBT Announce Blood Group Genotyping Test for Patients with Inherited Blood Disorders to Limit Transfusion Side Effects .....	2
BRIEFLY NOTED.....	3
PEOPLE.....	3
WORD IN WASHINGTON .....	4
ABC Partnership with Association of Chamber of Commerce Executives .....	5
ABC HR Education Webinar Announced.....	5
Program Available for 2024 ABC Annual Meeting .....	6
Registration Is Open for 2024 ADRP Annual Conference.....	6
RESEARCH IN BRIEF .....	7
GLOBAL NEWS .....	7
COMPANY NEWS .....	8
CALENDAR.....	9
POSITIONS.....	10

**Please Note:** The ABC Newsletter will not be published on Feb. 2nd. We will resume regular publication on Feb. 9<sup>th</sup>. Thank you for your continued interest.

## Second Edition of the U.S. Blood Donation Statistics and Public Messaging Guide Available

America's Blood Centers and ADRP, the Association for Blood Donor Professionals, [announced](#) the release of the new edition of the [U.S. Blood Donation Statistics and Public Messaging Guide](#), capturing the changes happening across the landscape of blood donation and transfusion nationally.

This latest edition of [the guide](#) features more than 40 verified statistics, including data on the U.S. blood supply, donor demographics, and the impact of blood transfusions on patient populations. It also highlights the COVID-19 pandemic's significant impact on the national blood supply as well as how donations from younger generations and diverse donors are critical to the long-term stability of the U.S. blood supply.

Some statistics of note that have been updated are:

- **Gender Shift:** In 2021, there was a notable gender shift among blood donors, with female donors making up 54.1 percent and male donors making up 45.9 percent. This marks a change from the 2019 data, where there were 51 percent male donors and 49 percent female donors.
- **Minority Donors:** Data shows a substantial 35.4 percent decrease in minority donors in 2021 compared to 2019, signifying the urgent need to increase the number of donors across underrepresented minority groups.
- **Impact of COVID-19:** The pandemic had a significant impact on blood donation, especially among younger donors given the cancellation of school-based drives. There was a 60.7 percent drop in donations from 16–18-year-olds and a 31.9 percent decrease in donations from 19–24-year-olds in 2021 compared to 2019.
- **Changing Age Demographics:** There was a 40.7 percent increase in donors aged 65 and older in 2021 compared to 2019, highlighting the need for focused recruitment efforts on younger generations.

Other widely used statistics included in the guide are insights into the number of patients each donation can help, the percentage of the eligible U.S. population that donates blood annually, the frequency of blood transfusions in the U.S., and the

(continued on page 2)



## U.S. Blood Donation Statistics and Public Messaging Guide Available (continued from page 1)

average number of blood donations each day in the country. The U.S. *Blood Donation Statistics and Public Messaging Guide* also features sample social media graphics and customizable infographics that highlight key statistics.

(Source: ABC and ADRP [News Release](#), 1/22/24) 💧

## **NHSBT Announce Blood Group Genotyping Test for Patients with Inherited Blood Disorders to Limit Transfusion Side Effects**

NHS Blood and Transplant (NHSBT), the national blood provider for England and transplant services for the United Kingdom (UK), is [partnering](#) with NHS England health services to offer patients with inherited blood disorders such as sickle cell disease and thalassemia, “a world-first ‘blood matching’ genetic test [to] better match their future blood transfusions, reducing the risk of side effects and offering more personalized care.”

According to a NHSBT news release, “[t]he DNA analysis of a patient’s blood groups may allow for more accurate matching for people who need transfusions and help find the best compatible blood for patients with complex requirements. This program will complement a separate program to test some donor’s blood. Lifesaving transfusions are commonly used to treat rare inherited blood disorders, but around a fifth of patients develop antibodies against certain blood groups following transfusion. They can then experience delays [in] treatment due to the difficulty in finding enough matching blood and sometimes blood transfusion reactions. To help improve blood-matching and reduce the risk of antibodies developing, NHS England, in partnership with NHS Blood and Transplant (NHSBT), is encouraging patients with sickle cell, thalassaemia and transfusion-dependent rare inherited anaemias to have this test taken alongside their routine hospital blood tests.” The news release also noted that, “in England, there are around 17,000 people living with sickle cell disorder, with 250 new cases a year.”

(Source: NHSBT [News Release](#), 1/22/24) 💧



The *ABC Newsletter* (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2024 by America’s Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher (ABC members need not obtain prior permission if proper credit is given).

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognizes the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies, and programs that increase awareness about the need for blood donation; and serve as a thought leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

### **America’s Blood Centers**

Chief Executive Officer: Kate Fry  
 Chief Medical Officer: Jed Gorlin  
 Editor: Mack Benton  
 Subscriptions Manager: Leslie Maundy  
**Annual Subscription Rate: \$420**

Send subscription queries to [memberservices@americasblood.org](mailto:memberservices@americasblood.org)  
 America’s Blood Centers  
 1717 K St. NW, Suite 900, Washington, DC 20006  
 Phone: (202) 393-5725  
 Send news tips to [newsletter@americasblood.org](mailto:newsletter@americasblood.org).



## BRIEFLY NOTED

The U.S. District Court, District of Massachusetts, [ruled](#) on a preliminary motion in the Verax Biomedical, Inc. [lawsuit](#) against the American Red Cross. The court ruled that the American Red Cross cannot be sued under the Sherman Antitrust Act, because it is not, “a separate antitrust person from the U.S.” The court allowed the lawsuit to move forward on state law claims of, “tortious interference with contractual relations” and violation of Massachusetts consumer protection law. The Verax lawsuit alleges that the American Red Cross, “leverage[ed] its power in the market for platelets to monopolize the market for mitigation services, in violation of the Sherman Act...[and] made false and disparaging statements about PGDprime™ to Verax’s customers, in violation of state law.”

(Source: U.S. District Court, District of Massachusetts [Ruling](#), 1/19/24)

The Centers for Disease Control and Prevention (CDC) in [partnership](#) with the American Society for Clinical Pathology (ASCP) have a series of webinars titled “Building Bridges Across the Laboratory Community.” Included in the five-part series are:

- “Responding to Emerging Outbreaks: Sharing the Load among Laboratory System Partners” (February 28<sup>th</sup>);
- “Supporting DE&I Initiatives in the Laboratory Workforce” (March 27<sup>th</sup>);
- “Partnerships Supporting Laboratory Training and Fellowships” (April 24<sup>th</sup>);
- “Twinning and Sharing Best Practices: Regional Partnerships” (May 15<sup>th</sup>); and
- “Partnerships in Service of Effective Data Sharing” (June 26<sup>th</sup>).

[Registration](#) is open for the series. The webinars are part of the [OneLab™ Initiative](#).

(Source: ASCP and CDC [Webinars](#), 1/26/24) 💧

## PEOPLE

The California Blood Bank Society (CBBS) recently announced that it will recognize three individuals at its upcoming Annual Meeting in May. **Mike Busch, MD, PhD** (University of California San Francisco/Vitalant) will be honored with the [Perkins-Garratty Award Lecture](#), which is, “awarded to an individual committed to the education, training, research and/or the practice of a scientific nature pertaining to transfusion medicine, [who] has demonstrated a commitment to transfusion medicine or cellular therapy, and has applied new insights or new technologies to relevant scientific questions that have led to seminal contributions to the field. Dr. Busch’s lifetime dedication to research and education in the field of transfusion medicine epitomizes the spirit of both Herbert Perkins and George Garratty.” **Alyssa Ziman, MD** (UCLA) is being recognized with the [Goldfinger Award Lecture](#), which goes to, “a physician who has demonstrated throughout their career a dedication to the practice of clinical transfusion medicine through the training of future transfusion medicine physicians and the pursuit of innovation within the field. Dr. Ziman’s lifetime dedication to transfusion medicine and training in the field epitomizes the spirit of Dr. Goldfinger.” **Karen Rodberg** (American Red Cross) is being honored with the [Ledin Award Lecture](#), which recognizes, “an individual committed to the education, training, and/or the practice of medical technology and blood banking and has demonstrated a commitment to transfusion medicine. Ms. Rodberg’s lifetime dedication to training and teaching in the field of transfusion medicine epitomizes the spirit of Suzanne Ledin.”

(Source: CBBS Announcement, 1/18/24) 💧





## WORD IN WASHINGTON

The U.S. Food and Drug Administration (FDA) published a [notice](#) in the *Federal Register* titled, “**Conducting Remote Regulatory Assessments- (RRAs) Questions and Answers; Revised Draft Guidance for Industry; Availability.**” According to the agency, “[t]he draft guidance, once finalized, describes how FDA will use RRAs for FDA regulated products. The revised draft guidance reflects FDA’s consideration of comments to the July 2022 draft guidance, as well as revisions to align with recent changes in law concerning mandatory records requests. [FDA] welcome[s] public comments during the 60-day comment period. The [agency] uses a robust, risk-based oversight approach to ensure the continued safety of the nation’s food and medical product supply. An RRA is an examination of an FDA-regulated establishment and/or its records, conducted entirely remotely, to evaluate compliance with applicable FDA requirements. Some of the tools include remote records requests, remote livestreaming video of operations, teleconferences, and screen sharing. These approaches have enabled the agency to provide oversight to as many facilities as possible when travel was restricted while continuing to deploy our resources where possible to protect consumers and patients and promote public health. For example, throughout the pandemic, the FDA used RRAs, domestically and abroad, for certain FDA-regulated products to help the agency conduct oversight, mitigate risk, and meet critical public health needs when inspections could not be conducted. Due to the success of these tools, the agency will continue to use RRAs, as appropriate, in overseeing regulated industry and ensuring the safety and effectiveness of all types of regulated products, supplementing critical oversight tools such as inspections.” Comments are due by March 26<sup>th</sup>.

(Source: *Federal Register* [Notice](#), 1/26/24)

The FDA [announced](#) that it has issued “**safety labeling change notification letters to all manufacturers of licensed BCMA-directed and CD19-directed genetically modified autologous CAR T cell immunotherapies requiring a revision to the package insert due to risk of T cell malignancies, with serious outcomes, including hospitalization and death.**” This change notification comes in the wake of the agency publishing a [safety communication](#) in November 2023 noting that FDA was investigating reports of T cell malignancy in individuals who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies. The January 23<sup>rd</sup> announcement explained that the agency, “considers the serious risk of T cell malignancy to be applicable to all BCMA- and CD19-directed genetically modified autologous T cell immunotherapies. The letters notify manufacturers of each such licensed product to update the package insert to include available information related to the risks and to update the Medication Guide for these products to identify the possibility of the increased risk of getting cancers, including certain types of cancers of the immune system...The FDA considers the serious risk of T cell malignancy to be applicable to all BCMA- and CD19-directed genetically modified autologous T cell immunotherapies. The letters notify manufacturers of each such licensed product to update the package insert to include available information related to the risks and to update the Medication Guide for these products to identify the possibility of the increased risk of getting cancers, including certain types of cancers of the immune system.”

(Source: FDA [Announcement](#) 1/23/24) 💧

### Upcoming ABC Webinars & Virtual Events – Don’t Miss Out!

- **America’s Blood Centers (ABC) Human Resources (HR) Education Webinar: Developing Leaders for Tomorrow & Employee Conflict Resolution** – Feb. 20<sup>th</sup>. More information available to ABC Members including a link to registration in [MCN 24-006](#).
- **ADRP, the Association for Blood Donor Professionals Webinar: Whole Blood-Derived Platelets - Maximize Every Donor's Gift.** Feb. 21<sup>st</sup> [Registration](#) is open. More information available [here](#).



**America's Blood Centers**  
It's About *Life*.

## INSIDE ABC

*The programs and services described in the Inside ABC section are available to ABC member blood centers and their staffs only, unless otherwise specified.*

### **ABC Partnership with Association of Chamber of Commerce Executives**

America's Blood Centers recently [partnered](#) with the Association of Chamber of Commerce Executives (ACCE) to encourage businesses to host blood drives. As the trend of virtual and hybrid work continues, the percentage of blood collected at business-based mobile blood drives has declined, adding to the challenge of an already shrinking number of individuals donating blood each year. In response to this concerning trend, the business community is taking steps to strengthen the blood supply during National Blood Donor Month and beyond. Collaborating with community blood centers, businesses are raising awareness about the importance of blood donation, encouraging employees to donate at locations convenient to them, and urging other organizations to also get involved in this important cause. "The Association of Chamber of Commerce Executives (ACCE) is proud to partner with ABC to raise awareness and encourage chambers of commerce to consider hosting a blood drive. Chambers can leverage their strength as a community leader and convener to help reverse the declining number of blood donors and business-based blood drives. Partnering with your local blood center makes hosting a blood drive easy," said Sheree Anne Kelly, president and chief executive officer of ACCE, in the news release. ABC has also developed a complimentary [Workplace Workbook](#), designed to empower organizations to enhance their collaboration with local community blood centers and amplify the life-saving impact of blood donation. This comprehensive resource offers information into the significance of blood donation in local communities, an in-depth overview of the blood donation process, guidance on hosting and promoting successful blood drives, and more. Organizations are encouraged to download and use this resource. Please Contact ABC Director of Strategic Communications and National Partnerships [Jeff Gohringer](#) with questions.

(Source: ABC [News Release](#), 1/25/24)

### **ABC HR Education Webinar Announced**

The next ABC Human Resources (HR) Education Webinar will take place on February 20<sup>th</sup> at 3 p.m. EST. The webinar will cover:

- "Developing Leaders for Tomorrow;" and
- "Employee Conflict Resolutions."

Featured speakers include Maria Brcka of LifeServe and Stephanie Rue of SunCoast Blood Centers. The webinar is not only intended for HR professionals, but also all ABC members who would like to learn more about developing their staff and strengthening professional interpersonal skills. More information, including a link to registration, is available to ABC members in [MCN 24-006](#). Please contact ABC Director of Scientific and Technical Operations [Betzy Gonzalez, MS, BB\(ASCP\)](#) with questions.

(Source: [MCN 24-006](#), 1/26/24)

(continued on page 6)





INSIDE ABC (continued from page 5)

### Program Available for 2024 ABC Annual Meeting

Registration is open for the ABC 2024 Annual Meeting and the program is available. The meeting will take place March 4<sup>th</sup>-6<sup>th</sup> in Arlington, Va. at the Ritz-Carlton in Pentagon City and features several exciting changes, including expanded content offerings and a new format. With a focus on advocacy, leadership, operations, and science and medicine, the program will feature a mix of general and breakout sessions, external speakers, blood center-led case studies, committee and council meetings, networking events, and more. Awards of Excellence (AoE) winners will be recognized throughout the Annual Meeting and at a reception on Capitol Hill, where we can celebrate their achievements with fellow meeting attendees, members of Congress and their staff, our federal agency partners, Blood Advocacy Week partners, and more. Secure your room today to take advantage of the group rate. The deadline to book a room is February 16<sup>th</sup>. Sponsorship opportunities are also available. Contact us with any questions.

### Registration Is Open for 2024 ADRP Annual Conference

Register today for the 2024 ADRP Annual Conference! Join more than 400 blood center professionals in St. Louis, Mo. May 14<sup>th</sup>-16<sup>th</sup> at The St. Louis Union Station Hotel. Take advantage of the member-only early bird discount rate by registering by January 31<sup>st</sup>. This year's conference will feature keynotes Jason Kotecki, an expert at helping people "Escape Adulthood" in order to beat burnout and become more innovative and creative by breaking rules that do not exist, and Candy Whirley, a recognized motivational speaker, leadership, and team building expert. The 2024 ADRP Annual Conference is your opportunity to gain insights into industry trends, exchange ideas, and share information with your peers, while taking advantage of networking opportunities. Attendees will be able to participate in pre-conference workshops, educational sessions, roundtables, and have access to an expansive exhibit hall. Learn more about available exhibitor and sponsorship opportunities. Remember to book your hotel room by April 19<sup>th</sup> for the discounted rate. Please contact us with questions.


# More draw time. Less charge time.

Get the longest battery life on the market with the HemoFlow 500 blood scale/mixer.



**APPLIED SCIENCE**  
STRATEGICALLY SIMPLE SOLUTIONS

Average Draws Per Battery Charge Comparisons



HemoFlow delivers **2.3x** more draws per charge than leading competitors

## RESEARCH IN BRIEF

**Anti-D Formation In Patients With and Without a Transplant History.** A [study](#) in *Vox Sanguinis*, “analyzed the incidence of D alloimmunization in solid organ transplant recipients with D-negative phenotype who were given D-positive red blood cell products.” The researchers explained that, “[t]hese results were compared with the D-negative phenotype patients who received D-positive red blood cell products for non-transplant surgeries.” The study included, “[a]ll D-negative patients who received  $\geq 1$  unit of D-positive red cells between January 2011 and December 2020...A total of 76 D-negative patients who fulfilled eligibility criteria were identified [for] the study, of which 22 patients (29.9 percent) had a history of solid organ transplant. A total of 705 D-positive red blood cell products were used for 76 patients (mean = 9.3 units, range = 1–65 units).” The authors noted that, “[n]ew red cell antibodies were identified in 15 of the 76 total patients (19.7 percent) after transfusion with red blood cell[s].” None of the transplant patients developed new anti-D; in contrast, 12 of the non-transplant patients developed new anti-D (OR = 0; 95 percent CI, 0.00–0.78;  $p = 0.01$ ). When the results were generalized to include all new red cell antibodies, only one transplant patient developed a new anti-E while 14 nontransplant patients developed new alloantibodies (OR = 0.14; 95 percent CI, 0.00–1.03;  $p = 0.05$ ).” Findings of the study included, “that patients who received D-positive red blood cell[s] in the perioperative period of solid organ transplant had a much lower likelihood of alloimmunization. The inclusion of other types of solid organ transplantation [liver, heart, lung, and multi-organ] indicates that this significantly reduced risk of anti-D formation may be generalizable across patients on post-transplant immunosuppression and suggests that prophylactic D matching for red cell[s] may not be strictly indicated for transplant patients.” The study concluded that, “in addition to gender and age, immunosuppression history should be an important factor when estimating the risk of anti-D formation and determining indications for prophylactic D matching. Transfusion services can implement this by discussing bleeding risk and transfusion plans with the clinical team before transplant surgeries for D-negative patients. This could be pivotal for D-negative inventory management in the setting of frequent national blood shortages.”

**Citation:** Wali, J.A., Abdelmonem, M., Nguyen, A., Shan, H., Pandey, S., and Yunce M. [Incidence of formation of anti-D between patients with and without a history of solid organ transplant](#). *Vox Sang*. 2024.

*Contributed by Richard Gammon, MD, Medical Director at OneBlood* 💧

## GLOBAL NEWS

**The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has [initiated](#) reviews of data on, “secondary malignancies related to T-cells (cancers that begin in a type of white blood cells called T-cells), including T-cell lymphoma and leukemia, for the six approved chimeric antigen receptor (CAR) T-cell medicines.”** According to agency, “the PRAC is now reviewing all available evidence, including information on 23 cases of various types of T-cell lymphoma or leukemia in EudraVigilance, the European Union (EU) database of adverse reactions to medicines, and will decide on the need for any regulatory action...CAR T-cell based gene therapy products belong to a type of personalized cancer immunotherapies where patients’ white blood cells (T-cells) are reprogrammed and re-injected to attack the cancer...A secondary malignancy is when a patient who has cancer (current or previous) develops a second cancer different from the first cancer.” The U.S. Food and Drug Administration (FDA) [announced](#) a similar review in November 2023. This month, the agency [issued](#), “safety labeling change notification letters to all manufacturers of licensed BCMA-directed and CD19-directed genetically modified autologous CAR T cell immunotherapies requiring a revision to the package insert due to risk of T cell malignancies, with serious outcomes, including hospitalization and death. The FDA considers the serious risk of T cell malignancy to be applicable to all BCMA- and CD19-directed genetically modified autologous T cell immunotherapies. The letters notify manufacturers of each such licensed product to update the package insert to include available information related to the risks and to update the Medication

(continued on page 8)

GLOBAL NEWS (continued from page 7)

Guide for these products to identify the possibility of the increased risk of getting cancers, including certain types of cancers of the immune system.”

(Source: EMA [Statement](#), 1/12/24) ◆

## COMPANY NEWS

**Applied Science** recently [announced](#) the launch of a whole blood collection automated solution, the HemoFlow 500 series of blood mixer and scale devices and HemoVue. According to a company news release, the former is a, “cloud-based service that integrates with both the HemoFlow 500 and existing HemoFlow 400 devices to provide real-time operational data and analytics that significantly improve blood collection and related processes...the combined solution, coupled with its bi-directional communication with existing BECS systems, provides customers with a paperless, automated whole blood collection system that removes the friction of manual data entry, optimizes each donation, eliminates process errors, reduces waste, enhances profitability, and allows phlebotomists to focus on caring for donors.”

(Source: Applied Science [News Release](#), 1/18/24)

**Beam Therapeutics** has [dosed](#) the first patient in its phase I/II clinical trial of its investigational cell therapy to treat sickle cell disease. According to a company news release, the investigational cell therapy is, “designed to efficiently and uniformly increase fetal hemoglobin (HbF) in red blood cells without relying on double stranded breaks, offering a potentially best-in-class profile. Preclinical models suggest base editing could lead to improved HbF induction and lower residual disease-causing hemoglobin S compared to existing gene therapy options. The first patient [successfully achieved] engraftment in the [clinical trial], an open-label, single-arm, multicenter study evaluating the safety and efficacy of [the investigational cell therapy] in adult patients with severe sickle cell disease. Treatment with the [therapy], in which the edited cell product is delivered in an autologous bone marrow transplant, will occur on a sequential basis for the first three patients treated in the trial, and then will be given in parallel for all subsequent patients.”

(Source: Beam Therapeutics [News Release](#), 1/8/24)

**Addimmune** is set to [begin](#) a phase Ib trial of its investigational gene therapy to treat patients with HIV. A report in *Clinical Trials Arena* indicated that participants in the phase Ia trial, “which investigated the [investigational] HIV [gene therapy] candidate together with antiretroviral therapy, did not experience any serious adverse events or rejection.” The upcoming phase Ib trial will, “include 24 patients who will undergo leukapheresis to remove T cells. The cells will then be developed and dosed with AGT103-T before they are introduced back into the body,” according to *Clinical Trials Arena*.

(Source: *Clinical Trials Arena*, “[Addimmune to investigate HIV gene therapy without SOC in Phase Ib trial](#),” 1/12/24) ◆







## NEW on CollABOrate

# COLLABORATE

SHARE STRATEGIC ADVICE | SOLVE CHALLENGES | DEVELOP NEW APPROACHES

Recent discussion topics on the ABC [CollABOrate](#) Online Member Community include:

- [Alternative Blood Mobiles](#) (COLLECTIONS & DONOR SERVICES)
- [Pulse Recheck Policy](#) (COLLECTIONS & DONOR SERVICES)
- [Signs and Symptoms of Reaction](#) (COLLECTIONS & DONOR SERVICES)
- [Venipuncture Loss Rates](#) (COLLECTIONS & DONOR SERVICES)
- [Alternative Phlebotomy Arm Scrub](#) (COLLECTIONS & DONOR SERVICES)
- [Donor Notification of Test Results](#) (QUALITY BYTES)
- [One Dad Can](#) (COMMUNICATIONS & DONOR RECRUITMENT)

ABC members are encouraged to [login](#) and join the conversations today!

## CALENDAR

*Note to subscribers: Submissions for a free listing in this calendar (published weekly) are welcome. Send information to [newsletter@americasblood.org](mailto:newsletter@americasblood.org). (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)*

### 2024

Feb.7-8. **International Plasma and Fractionation Association & EBA Symposium on Plasma Collection and Supply. Leiden, Netherlands.** [Registration](#) is open. More information available [here](#).

Feb. 20. **America's Blood Centers (ABC) Human Resources Education Webinar: "Developing Leaders for Tomorrow & Employee Conflict Resolution."** More information and a link to registration are available to ABC members in [MCN 24-006](#).

Feb. 21. **ADRP, the Association for Blood Donor Professionals Webinar: "Whole Blood-Derived Platelets - Maximize Every Donor's Gift."** [Registration](#) is open. More information available [here](#).

Mar. 4-6. **America's Blood Centers (ABC) Annual Meeting. Arlington, Va.** [Registration](#) is open. More information available [here](#).

April 11-12. **International Haemovigilance Network Symposium. Athens, Greece.** [Registration](#) is open. More information available [here](#).

April 12-13. **BEST Meeting. Amsterdam, Netherlands.** More information is coming soon.

April 16-17. **International Plasma Protein Congress. Athens, Greece.** [Registration](#) is open. More information available [here](#).

April 17-18. **ABC Quality and Technical Workshop. St. Louis, Mo.** [Registration](#) is open. More information available [here](#).

May 3-4. **California Blood Bank Society (CBBS) Annual Meeting.** More information is coming soon.

(continued on page 10)



## CALENDAR (continued from page 9)

May 14-16. **2024 ADRP Annual Conference. St. Louis, Mo.** [Registration](#) is open. More information available [here](#).

May 15-16. **International Plasma and Fractionation Association/Paul-Ehrlich Institut[e] 30<sup>th</sup> International Workshop on Surveillance and Screening of Blood-borne Pathogens. Aarhus, Denmark.** [Registration](#) is open. More information available [here](#).

June 7-8. **2024 South Central Association of Blood Banks (SCABB) Annual Meeting and Exhibit Show. Orlando, Fla.** More information is coming soon.

June 23-27. **38<sup>th</sup> International Society of Blood Transfusion (ISBT) Congress. Barcelona, Spain.** [Registration](#) is open. More information available [here](#).

Sept. 4-6. **American Society for Clinical Pathology (ASCP). Chicago, Ill.** More information is coming soon.

Sept. 30- Oct. 3. **American Association of Tissue Banks (AATB). Denver, Colo.** More information is coming soon.

Oct. 19-22. **Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting. Houston, Texas.** More information is coming soon.

## 2025

May 20-21. **International Plasma Protein Congress. Warsaw, Poland.** More information is coming soon.

Oct. 25-28. **AABB Annual Meeting. San Diego, Calif.** More information is coming soon. 💧

## CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: [newsletter@americasblood.org](mailto:newsletter@americasblood.org)

## POSITIONS

**Vice President of Clinical Research and Quality Services.** Vitalant is currently seeking a results-driven **Vice President of Clinical Research and Quality Services** responsible for the strategic oversight and direction of quality and operational excellence. As the VP of Clinical Research and Quality Services, your scope will cover a variety of clinical and research activities, including biotherapies, reference lab and quality management. You will play a pivotal part in fostering strong relationships, facilitating business outcomes, and ensuring enhanced performance. You will hold a central position in embodying and promoting a commitment to perfection in all organizational endeavors, offering regulatory and compliance expertise while guiding a team of quality professionals in alignment with our people-centered values. At Vitalant, your impact is vital. As the Vice President of Clinical Research and Quality Services, you will have the opportunity to shape the future of our organization, contribute to life-saving initiatives, and be a part of a team that values excellence and innovation. This position will operate in the Scottsdale, AZ National Headquarters in a hybrid work environment. Please click [here](#) to apply.

**Director, Laboratory Services.** The Director, Laboratory Services reports to the Chief Medical Officer/CLIA Laboratory Director and is responsible for facilitating the design and implementation of the delivery of laboratory services, developing, and recommending strategies to improve services and clinical outcomes, reaching established goals, maintaining satisfactory outcomes, and contributing to the business plans and financial goals of the organization. The Director, Laboratory Services will provide oversight of San Diego Blood Bank's clinical and research laboratories. Educational requirements include MD or MD/PhD (doctoral-degree scientist) and board certification in anatomic/clinical pathology or clinical pathology (preferred). Eight years of progressively responsible and demonstrated experience in high-level management at a reference or health system laboratory is preferred, participation in FDA, State, Federal, and accrediting agency inspections with knowledge of regulatory accreditation and licensing requirements, and application of quality assurance principles. Please click [here](#) to view the full job description and apply.

(continued on page 11)

**POSITIONS** (continued from page 10)

**Transfusion Lab Supervisor Needed!** Join Florida's leading blood center, **OneBlood**, as a Blood Bank Lab Supervisor in Lakeland, FL. Bring your leadership, technical expertise, and management experience to support the transfusion testing procedures on patient and/or donor samples. Qualified candidates should possess three (3) or more years' experience in a clinical laboratory, preferably blood banking environment, including one (1) or more years' experience in supervision and management experience, as well as a valid and current Florida Clinical Laboratory Technologist license in Immunohematology or Blood Banking; Supervisor license strongly preferred. To apply and view a complete Job Description of this Lab Supervisor position, visit [www.oneblood.org/careers](http://www.oneblood.org/careers). OneBlood, Inc. is an Equal Opportunity Employer/Vet/Disability.

**Vice President, Quality & Regulatory Affairs (VPQRA).** The Vice President, Quality & Regulatory Affairs (VPQRA) leads the Organization's adherence to regulations and standards established by governing agencies (AABB, FDA, CLIA, State, OSHA, NRC, EU, etc.). Kentucky Blood Center is seeking qualified candidates to fill this key executive leadership role which is responsible for our Quality Assurance (QA) program and regulatory compliance activities. The position has oversight of the QA department and team, and reports to the CEO. Qualifications include MLS/CLS (ASCP) with preference given to candidates with a graduate degree, and blood banking experience. Relocation to the Lexington, Kentucky area required (assistance provided). For more information or to apply, visit <https://www.kybloodcenter.org/about-us/careers>.

**Hospital Services and Manufacturing Manager.** The Blood Bank of Alaska (BBA) is looking for a Hospital Services and Manufacturing Manager. The Hospital Services and Manufacturing Manager is responsible for ensuring there is an adequate blood supply to meet customer needs. Overseeing import of needed blood components and actively exporting excess blood products, as needed. Ensuring blood products are stored and monitored in compliance with FDA, AABB and Blood Bank of Alaska's (BBA) regulatory requirements. Ensuring adherence and compliance to BBA's Standard Operating Procedures (SOPs). Overseeing the processing, packing, and shipping of blood products. Overseeing the quality control program for storage of blood products. This position is full-time exempt. The Blood Bank of Alaska offers competitive wages and an exceptional benefits plan. We offer medical, dental, vision, life, and short/long term disability programs to qualified employees. Educational assistance, paid annual leave and holidays and a 401 (k) program are also available. The Blood Bank is an equal opportunity employer. Qualified applicants are considered for employment without regard to race, color, religion, national origin,

age, disability, marital/veteran status, or any other legally protected status. Interested candidates please apply online at <https://bloodbankofalaska.apscareerportal.com>. A complete job description can be found there as well.

**Director of Hospital Services and Manufacturing.** The Blood Bank of Alaska is looking for a Director of Hospital Services and Manufacturing. The Director of Hospital Services and Manufacturing is responsible for ensuring alignment of teams with organizational goals and compliance with regulatory guidelines. Participates as a member of the blood bank's management team in planning, program formulation and decision making with reference to the role, functions and technical support of the manufacturing and distribution of blood products. Fosters and enhances customer hospital relations. This person ensures a dedicated focus on the production and distribution of quality products in a timely manner while providing the highest level of customer service. Also ensures all procedures are followed and promotes a positive work environment. This position is full-time exempt. The Blood Bank of Alaska offers competitive wages and an exceptional benefits plan. We offer medical, dental, vision, life, and short/long term disability programs to qualified employees. Educational assistance, paid annual leave and holidays and a 401 (k) program are also available. The Blood Bank is an equal opportunity employer. Qualified applicants are considered for employment without regard to race, color, religion, national origin, age, disability, marital/veteran status, or any other legally protected status. Interested candidates please apply online at <https://bloodbankofalaska.apscareerportal.com>. A complete job description can be found there as well.

**Laboratory Services Manager.** The Blood Bank of Alaska is looking for a Laboratory Services Manager. Under the general direction of the Director of Laboratory Services, this person is responsible for oversight of daily laboratory operations ensuring that laboratory product QC and donor test results meet CLIA, AABB and FDA compliance standards/regulations for the manufacture of blood products. The Laboratory Services Manager is also responsible for oversight of laboratory personnel. This position is full-time exempt. The Blood Bank of Alaska offers competitive wages and an exceptional benefits plan. We offer medical, dental, vision, life, and short/long term disability programs to qualified employees. Educational assistance, paid annual leave and holidays and a 401 (k) program are also available. The Blood Bank is an equal opportunity employer. Qualified applicants are considered for employment without regard to race, color, religion, national origin, age, disability, marital/veteran status, or any other legally protected status. Interested candidates please apply online at <https://bloodbankofalaska.apscareerportal.com>. A complete job description can be found there as well.

(continued on page 12)

POSITIONS (continued from page 11)

**Manager of Donor Services.** The Blood Connection is seeking a Manager of Donor Services for our operations based out of Rock Hill, SC. This position will oversee donor collection operations within their assigned divisional territory. This position provides leadership and discipline to direct reports, interviews, and hires staff, and ensures staff are appropriately trained. We offer a generous benefits package including a substantial 401k, 30 days PTO, potential company bonuses, cell phone stipend, and tuition reimbursement. Join our team and help create a positive change in your community. *Prospective candidates may be eligible for relocation assistance.* How to apply: [Manager of Donor Services Application](#).

**Manager of Donor Resources.** The Blood Connection is expanding our operations into Virginia! We are one of the fastest growing blood centers in the country and we are seeking a Manager of Donor Resources who will provide management and oversight of the Donor Resources department as we expand into this new territory. The ideal candidate for this position possesses strong leadership and organizational skills with a proven ability to meet organizational goals. We offer a generous benefits package including a substantial 401k, 30 days PTO, potential company bonuses, cell phone stipend, and tuition reimbursement. Join our team and help create a positive change in your community. *This role is based in Roanoke, VA. Prospective candidates may be eligible for relocation assistance.* How to apply: [Manager of Donor Resources Application](#). ♦